Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Subjects With Inflammatory Bowel Disease.
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs BAY 949392 (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Diagnostic use
- 19 Aug 2018 Status changed from not yet recruiting to recruiting.
- 12 Jun 2018 New trial record